WHAT IS CLAIMED IS:

1. Use of an effective amount of cortexolone-17α-propionate and an effective amount of minoxidil in the manufacture of a medicament for treating hair loss in a subject in need thereof, wherein the medicament is to be administered topically.

2. The use of claim 1, wherein cortexolone-17α-propionate is to be co-administered in an amount from at least 1 wt% to about 20 wt%.

3. The use of claim 1, wherein minoxidil is to be co-administered in an amount from about 0.1 wt% to about 20 wt%.

4. The use of any one of claims 1-3, wherein the cortexolone-17α-propionate and minoxidil are to be co-administered sequentially, preferably they are in separate pharmaceutical formulations.

5. The use of any one of claims 1-4, wherein the cortexolone-17α-propionate and minoxidil are to be co-administered simultaneously, preferably they are in the same pharmaceutical formulation.

6. The use of claim 5, wherein the pharmaceutical formulation is a liquid or semi-solid formulation.

7. The uses of claim 6, wherein the pharmaceutical formulation is a solution, a suspension, an emulsion, a microemulsion, a cream, a paste, a gel, an ointment, or a foam, preferably said pharmaceutical formulation is a solution.

8. The use of claim 7, wherein the solution comprises water, saline, a buffered saline solution, a polyol, a polyol ether, a C_1-C_7 alcohol, or a combination thereof.

9. The use of any one of claims 6-8, wherein the pharmaceutical formulation further comprises at least one additive selected from an acid, a buffer, an antioxidant, an emulsifier, a penetration enhancer, a moisturizer, a preservative, a chelating agent, and combinations thereof.

10. The use of any one of claims 1-9, wherein the cortexolone-17α-propionate is to be co-administered in a pharmaceutical formulation comprising less than about 5 wt% water.

11. The use of any one of claims 1-10, wherein the pharmaceutical formulation is to be co-administered topically once or twice daily.

12. The use of any one of claims 1-11, wherein the hair loss is alopecia, preferably the alopecia is androgenetic alopecia, alopecia areata telogen effluvium, anagen effluvium, traction alopecia, or a combination of any of the foregoing, more preferably the alopecia is androgenetic alopecia.

13. The use of claim 12, wherein the alopecia areata is selected from the group consisting of diffuse alopecia areata, alopecia areata monolocularis, alopecia areata multilocularis, ophiasis, alopecia totalis, and alopecia universalis.

14. A topical pharmaceutical formulation comprising cortexolone-17α-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

15. The topical pharmaceutical formulation of claim 14, wherein the cortexolone-17α-propionate is fully solubilized in the pharmaceutical formulation.

16. The topical pharmaceutical formulation of claim 14 or 15, wherein the pharmaceutical formulation comprises cortexolone-17α-propionate at a concentration from about 1 wt% to about 20 wt%.

17. The topical pharmaceutical formulation of any one of claims 15-16, wherein the pharmaceutical formulation comprises minoxidil at a concentration from about 0.1 wt% to about 20 wt%.

18. The topical pharmaceutical formulation of any one of claims 14-17, wherein the pharmaceutical formulation is a liquid or semi-solid formulation.

19. The topical pharmaceutical formulation of claim 18, wherein the liquid or semi-solid formulation is a solution, a suspension, an emulsion, a microemulsion, a cream, a paste, a gel, an ointment, or a foam, preferably the pharmaceutical formulation is a solution.

20. The topical pharmaceutical formulation of claim 18 or 19, wherein the solution comprises water, saline, a buffered saline solution, or a combination thereof.

21. The topical pharmaceutical formulation of any one of claims 14-20, wherein the pharmaceutical formulation comprises less than about 5 percent water by weight.

22. The topical pharmaceutical formulation of any one of claims 14-21, wherein the one or more pharmaceutically acceptable carriers are selected from the group consisting of a polyol, a polyol ether, and a C_1-C_7 alcohol, preferably C_1-C_7 alcohol is ethanol, isopropanol, methanol, or a combination thereof, more preferably the C_1-C_7 alcohol is ethanol.

23. The topical pharmaceutical formulation of claim 22, wherein the polyol is selected from the group consisting of ethylene glycol, propylene glycol, glycerol, hexanetriol, and combinations thereof, preferably the polyol is propylene glycol.

24. The topical pharmaceutical formulation of any one of claims 22-23, wherein the polyol ether is selected from the group consisting of polypropylene glycol, polyethylene glycol, polyethylene-polypropylene triblock copolymers, dipropylene glycol, diethylene glycol monoethyl ether, and combinations thereof, preferably the polyol ether is diethylene glycol monoethyl ether.

25. The topical pharmaceutical formulation of any one of claims 22-24, wherein the polyol is propylene glycol, the polyol ether is diethylene glycol monoethyl ether, and the C_1-C_7 alcohol is ethanol.

26. The topical pharmaceutical formulation of any one of claims 14-25, wherein the pharmaceutical formulation further comprises at least one additive selected from an acid, a buffer, an antioxidant, an emulsifier, a penetration enhancer, a moisturizer, a preservative, a chelating agent, and combinations thereof.

27. The topical pharmaceutical formulation of claim 26, wherein the antioxidant is selected from the group consisting of butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), ascorbyl palmitate, ascorbic acid, alpha tocopherol, propyl gallate, 2,4,5-

trihydroxybutyrophenone, 4-hydroxymethyl-2,6-di-tert-butylphenol, erythorbic acid, gum guaiac, thiodipropionic acid, dilauryl thiodipropionate, tert-butylhydroquinone, pharmaceutically acceptable salts or esters thereof, and combinations thereof, preferably the antioxidant is BHT, ascorbyl palmitate, or a combination of BHT and ascorbyl palmitate.

28. The topical pharmaceutical formulation of any one of claims 26-27, wherein the emulsifier is selected from the group consisting of PEG-15 hydroxystearate (polyoxyl-15-hydroxystearate), PEG-30 stearate, PEG-40 laurate, PEG-40 oleate, polysorbate 20, polysorbate 60, polysorbate 80, PEG-20 cetostearyl ether, polyoxyl 25 cetostearyl, cetomacrogol 1000, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate propylene glycol esters of fatty acids, polyglycerol esters of fatty acids, polyoxyl 5 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, caprylocapryl polyoxyil-8 glycerides, caprylocaproyl polyoxylglycerides, lauroyl polyoxylglycerides, oleoyl polyoxylglycerides, and combinations thereof, preferably the emulsifier is polysorbate 60, polysorbate 80, or a combination of polysorbate 60 and polysorbate 80.

29. The topical pharmaceutical formulation of any one of claims 26-28, wherein the penetration enhancer is selected from the group consisting of a diol, a polyol, a fatty acid, a fatty alcohol, a fatty acid ester, a surfactant, a pyrrolidone, and combinations thereof.

30. The topical pharmaceutical formulation of any one of claims 26-29, wherein the moisturizer is selected from the group consisting of a fatty alcohol, a fatty acid, a fatty acid ester, an oil, a polyethylene glycol, glycerin, an alpha hydroxy acid, and combinations thereof.

31. The topical pharmaceutical formulation of claim 30, wherein the moisturizer is cetyl alcohol, cetearyl alcohol, stearyl alcohol, stearic acid, isopropyl myristate, isopropyl palmitate, cocoa butter, lanolin, liquid paraffin, shea butter, a silicone oil, castor oil, a polyethylene glycol, glycerin, lactic acid, glycolic acid, malic acid, citric acid, tartaric acid, or a combination thereof.

32. The topical pharmaceutical formulation of any one of claims 26-31, wherein the buffer is a phosphate buffer, citrate buffer, lactate buffer, or a combination thereof.

33. Use of the topical pharmaceutical formulation of any one of claims 14-32 in the manufacture of a medicament for treating alopecia, wherein the topical administration of the pharmaceutical formulation for at least six months achieves a weighted average Hair Growth Assessment (HGA) score of about 0.30 in comparison with vehicle.

34. Use of the topical pharmaceutical formulation of any one of claims 14-32 in the manufacture of a medicament for treating alopecia, wherein the topical administration of the pharmaceutical formulation for at least six months achieves a weighted average Investigator's Global Assessment (IGA) score of about 0.43 in comparison with vehicle.

35. Use of the topical pharmaceutical formulation of any one of claims 14-32 in the manufacture of a medicament for treating alopecia, wherein the topical administration of the pharmaceutical formulation for at least six months is free from systemic antiandrogenic side-effects.

36. Use of the topical pharmaceutical formulation of any one of claims 14-32 in the manufacture of a medicament for treating alopecia, wherein the topical administration of the pharmaceutical formulation provides

a) a mean change from baseline in Target Area Hair Count equal to or higher than 9 hairs/cm^2 after 6 months of daily or BID application; or

b) a mean change from baseline in Target Area Hair Count equal to or higher than 10 hairs/cm^2 after 6 months of daily or BID application; or

c) a mean change from baseline in Target Area Hair Count equal to or higher than 11 hairs/cm^2 after 6 months of daily or BID application; or

d) a mean change from baseline in Target Area Hair Count equal to or higher than 12 hairs/cm^2 after 6 months of daily or BID application; or

e) a weighted average HGA score equal to or higher than 0.20 after 6 months of daily or BID application; or

f) a weighted average HGA score equal to or higher than 0.30 after 6 months of daily or BID application; or

g) a weighted average HGA score equal to or higher than 0.40 after 6 months of daily or BID application; or

h) a weighted average IGA score equal to or higher than 0.10 after 6 months of daily or BID application; or

i) a weighted average IGA score equal to or higher than 0.20 after 6 months of daily or BID application; or

j) a weighted average IGA score equal to or higher than 0.30 after 6 months of daily or BID application; or

k) a favorable (positive) HGA score in at least about 10 % of subjects after 6 months of daily or BID application; or

l) a favorable (positive) HGA score in at least about 20 % of subjects after 6 months of daily or BID application; or

m) a favorable (positive) HGA score in at least about 30 % of subjects after 6 months of daily or BID application; or

n) a favorable (positive) IGA score in at least about 10 % of subjects after 6 months of daily or BID application; or

o) a favorable (positive) IGA score in at least about 20 % of subjects after 6 months of daily or BID application; or

p) a favorable (positive) IGA score in at least about 30 % of subjects after 6 months of daily or BID application; or

q) a favorable (positive) IGA score in at least about 40 % of subjects after 6 months of daily or BID application.

37. Use of the topical pharmaceutical formulation according to any one of claims 14-32 in the manufacture of a medicament for the treatment of hair loss in a subject in need thereof.

38. The use according to claim 37, wherein the hair loss is alopecia.

39. The use according to claim 38, wherein alopecia is androgenetic alopecia, alopecia areata telogen effluvium, anagen effluvium, traction alopecia, or a combination of any of the foregoing.

40. The use according to claim 39, wherein the alopecia areata is selected from the group consisting of diffuse alopecia areata, alopecia areata monolocularis, alopecia areata multilocularis, ophiasis, alopecia totalis, and alopecia universalis.

41. The use according to claim 50, wherein alopecia is androgenic alopecia.